STEVEN GROSS, PA-C
Physician Assistant at 77 St, New York, NY

5770623, Jun 23, 1998

Nov 22, 1995

8/561717

Robert G. Kilbourn - Naperville IL
Steven S. Gross - New York NY
Roberto Levi - New York NY
Owen W. Griffith - Milwaukee WI

Board of Regents, The University of Texas System - Austin TX
Cornell Research Foundation, Inc. - Ithaca NY

A61K 31195

514565

A method for prophylaxis or treatment of an animal for systemic hypotension induced by internal nitrogen oxide production. The method involves administering a therapeutically effective amount of certain arginine derivatives to inhibit nitrogen oxide formation from arginine. Preferably N. sup. G -substituted arginine or an N. sup. G,N. sup. G -disubstituted arginine (having at least one hydrogen on a terminal guanidino amino group replaced by another atomic species) is administered to an animal possibly developing or already having such induced systemic hypotension. The arginine derivatives are preferably of the L configuration and include pharmaceutically acceptable addition salts. Prophylaxis or treatment of systemic hypotension in a patient which has been induced by chemotherapeutic treatment with biologic response modifiers such as tumor necrosis factor or interleukin-2 may be accomplished. Treatment of an animal for systemic hypotension induced by endotoxin, i. e.

5312835, May 17, 1994

May 29, 1992

7/890430

Robert G. Kilbourn - Houston TX
Steven S. Gross - New York NY
Owen W. Griffith - Milwaukee WI

Board of Regents, the University of Texas System - Austin TX
Cornell Research Foundation, Inc. - Ithaca NY

A61K 31195, A61K 31135

514565

The present invention involves a method for prophylaxis or treatment of an animal for systemic hypotension induced by endotoxin and/or a biological response modifier such as the cytokines, IFN, TNF, IL-1 or IL-2 and the like. Said method involves administering, preferably intravascularly, a therapeutically effective amount of dobutamine and an inhibitor of nitric oxide formation from arginine. Although preferable administration is intravascular, it is contemplated that other parenteral administration routes such as intraperitoneal, intramuscular or subdermal injection, for example, may prove useful. Enteral or topical administration of arginine analogs may also prove beneficial under certain clinical conditions.

5776979, Jul 7, 1998

Mar 31, 1995

8/338591

Robert G. Kilbourn - Houston TX
Steven S. Gross - New York NY
Owen W. Griffith - Milwaukee WI

Board of Regents, The University Of Texus System - Austin TX
Cornell Research Foundation, Inc. - Ithaca NY

A61K 31195

514565

The present invention involves a method for prophylaxis or treatment of an animal for systemic hypotension induced by endotoxin and/or a biological response modifier such as the cytokines, IFN, TNF, IL-1 or IL-2 and the like. The method involves administering, preferably intravascularly, a therapeutically effective amount of dobutamine and an inhibitor of nitric oxide formation from arginine.

5874433, Feb 23, 1999

Dec 19, 1995

8/574654

Steven S. Gross - New York NY

Cornell Research Foundation, Inc. - Ithaca NY

A01N 4366, A61K 3153, A61K 31495

514241

Inhibitor of the use of tetrahydrobiopterin as a cofactor for nitric oxide synthase, e. g. , substituted 4-phenyl(hydropyridines) such as 1-methyl-4-(3',4'-dihydroxyphenyl)-1,2,3,6-tetrahydropyridine or, 4-(3',4'-dihydroxyphenyl)-1,2,3,6-tetrahydropyridine) or tetrahydropterin analog which does not replace tetrahydrobiopterin as a substrate for nitric oxide synthase such as (6R,S)-6,7-dimethyl-tetrahydropterin or (6R,S)-tetrahydrofolic acid or 2,4-diamino-, 2,6-diamino, or 4,6-diamino mono- or disubstituted pyrimidines or the corresponding pyrimidine-3-oxides such as 2,4-diamino-6-(diethylamino)pyrimidine, 2,4-diamino-6-piperidino-pyrimidine-3-oxide, 2,4-diamino-6-hydroxypyrimidine, 4,6-diamino-2-hydroxypyrimidine or 2,5-diamino-4,6-dihydroxypyrimidine is administered to inhibit nitric oxide synthesis from arginine in vascular cells in a subject in need of such inhibition (e. g. , for prophylaxis or treatment of cytokine- or endotoxin-induced hypotension (e. g. , septic shock).

5216025, Jun 1, 1993

Jul 1, 1991

7/723480

Steven S. Gross - New York NY
Robert G. Kilbourn - Houston TX
Roberto Levi - New York NY

Board of Regents, The University of Texas System - Austin TX
Cornell Research Foundation, Inc. - Ithaca NY

A61K 31195, A61K 3700

514565

A method for treatment of an animal for systemic hypotension induced by internal nitric oxide production caused by endotoxin or cytokines. The method involves administering an. alpha. sub. 1 adrenergic agonist and an amount of an inhibitor of nitric oxide formation from argi Research relating to the development of this invention was supported by the United States Public Health Service grants which gives the United States government certain rights to use of the present invention.

6967219, Nov 22, 2005

Oct 10, 2002

10/268106

Steven S. Gross - New York NY, US
Michael S. Goligorsky - Stony Brook NY, US

Cornell Research Foundation, Inc. - Ithaca NY
The Research Foundation of the State University of New York - Albany NY

A61K031/195

514565, 514564

Premature vascular senescence is reversed or prevented in tissue or cells by contacting the tissue or cells with a hydroxyguanidine. This finds application in treatment of patients with a disorder associated with elevated levels of advanced glycation end products in blood or tissue, e. g. , patients with end stage renal disease or poorly controlled diabetes, and in contacting vascular tissue or cells ex vivo to prevent occurrence of premature senescence.